SHP656, a polysialylated recombinant factor VIII (PSA‐rFVIII): First‐in‐human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A

INTRODUCTION: SHP656 is the first factor VIII (FVIII) product developed using polysialylation (PSA) technology, in which full‐length recombinant (r) FVIII (anti‐haemophilic factor [recombinant]) is conjugated with a 20 kDa PSA polymer. AIM: To compare the safety, immunogenicity and pharmacokinetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiede, Andreas, Allen, Geoffrey, Bauer, Alexander, Chowdary, Pratima, Collins, Peter, Goldstein, Brahm, Jiang, Hongyu Jeanne, Kӧck, Kathleen, Takács, István, Timofeeva, Margarita, Wolfsegger, Martin, Srivastava, Shouryadeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027936/
https://www.ncbi.nlm.nih.gov/pubmed/31778283
http://dx.doi.org/10.1111/hae.13878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027936/
https://www.ncbi.nlm.nih.gov/pubmed/31778283
http://dx.doi.org/10.1111/hae.13878

Ejemplares similares